Crossmark

Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s13014-020-01606-3

Published Online: 2020-07-29

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Huang, Jin

Gu, Fei

Ji, Tianlong

Zhao, Jing

Li, Guang
Funding

Funding for this research was provided by:

Chinese Society of Clinical Oncology (Y-G201801-055)
License Information

Text and Data Mining valid from 2020-07-29

Version of Record valid from 2020-07-29
More Information

Article History

Received: 8 October 2019

Accepted: 30 June 2020

First Online: 29 July 2020

Ethics approval and consent to participate

: The trial was registered with Chinese clinical trial registry (ChiCTR1800015069). We declare that this study was approved by the institutional review board at Medical Science Research Ethics Committee of The first hospital of China Medical University (2018–137-3). Patients were required to provide written informed consent to participate in this research.

: Not applicable.

: No conflict of interest exits in the submission of this manuscript.

Document is current

Any future updates will be listed below